Arbutamine is a synthetic β-adrenergic receptor agonist with a unique pharmacological profile. It has been studied for its potential therapeutic applications in treating cardiovascular diseases, such as heart failure and hypertension. The synthesis of arbutamine involves a multi-step process, starting from readily available starting materials. The compound's mechanism of action involves stimulating β-adrenergic receptors, leading to increased heart rate, contractility, and blood flow. Arbutamine has been shown to exhibit positive inotropic effects, meaning it can enhance the force of heart muscle contractions. It is also known to have vasodilatory effects, relaxing blood vessels and improving blood flow. Studies have explored the potential benefits of arbutamine in improving cardiac function and reducing symptoms in patients with heart failure. Additionally, research has investigated its role in managing hypertension by lowering blood pressure. Arbutamine's unique pharmacological profile, coupled with its potential therapeutic applications, makes it an interesting subject of study in the field of cardiovascular medicine.'
arbutamine: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 60789 |
| CHEMBL ID | 1201251 |
| CHEBI ID | 50580 |
| SCHEMBL ID | 521645 |
| MeSH ID | M0205855 |
| Synonym |
|---|
| arbutamine |
| DB01102 |
| arbutamina |
| CHEBI:50580 , |
| arbutaminum |
| 4-[(1r)-1-hydroxy-2-{[4-(4-hydroxyphenyl)butyl]amino}ethyl]benzene-1,2-diol |
| 128470-16-6 |
| 4-[(1r)-1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol |
| CHEMBL1201251 |
| arbutamina [inn-spanish] |
| arbutaminum [inn-latin] |
| unii-b07l15yaev |
| b07l15yaev , |
| arbutamine [inn:ban] |
| arbutamine [who-dd] |
| arbutamine [vandf] |
| arbutamine [inn] |
| (r)-3,4-dihydroxy-.alpha.-(((4-(p-hydroxyphenyl)butyl)amino)methyl)benzyl alcohol |
| arbutamine [mi] |
| 1,2-benzenediol, 4-(1-hydroxy-2-((4-(4-hydroxyphenyl)butyl)amino)ethyl)-, (1r) |
| SCHEMBL521645 |
| DTXSID00155908 |
| Q4784959 |
| CS-0006131 |
| HY-16056 |
| 1,2-benzenediol, 4-[(1r)-1-hydroxy-2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]- |
| MS-24685 |
| EN300-18815718 |
| AKOS040732463 |
Arbutamine is a new beta-adrenergic agonist with potent chronotropic and inotropic properties. It has been developed as a pharmacologic stress agent for the diagnosis of coronary artery disease.
Arbutamine echocardiography is an effective and safe pharmacologic stress test technique. Arbutamine was well tolerated, and there were no serious adverse events.
| Excerpt | Relevance | Reference |
|---|---|---|
| ", multiplied by in vivo concentration, electrode area, current, and dosing time)." | ( Quantitative prediction of transdermal iontophoretic delivery of arbutamine in humans with the in vitro isolated perfused porcine skin flap. Hillman, RS; Mishky, LM; Riviere, JE; Williams, PL, 1992) | 0.52 |
| " Beta-adrenergic blockade with propranolol shifted the agonist's dose-response curves for heart rate and contractility to the right; however, low doses of dobutamine exhibited a negative chronotropic effect and increased the total peripheral vascular resistance." | ( A novel catecholamine, arbutamine, for a pharmacological cardiac stress agent. Abou-Mohamed, G; Caldwell, RW; Myers, T; Nagarajan, R, 1996) | 0.6 |
| " During the early arbutamine study, the sensitivity for predicting functional recovery was highest at a dosage of 50 ng/kg/min, which also produced tachycardia." | ( Arbutamine stimulation detects viable myocardium 4 weeks after coronary occlusion. Feigenbaum, H; Johnson, M; Kisanuki, A; Ryan, T; Sawada, SG; Segar, DS; Tei, C, 2001) | 2.09 |
| Role | Description |
|---|---|
| beta-adrenergic agonist | An agent that selectively binds to and activates beta-adrenergic receptors. |
| cardiotonic drug | A drug that has a strengthening effect on the heart or that can increase cardiac output. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| catecholamine | 4-(2-Aminoethyl)pyrocatechol [4-(2-aminoethyl)benzene-1,2-diol] and derivatives formed by substitution. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Arbutamine Action Pathway | 47 | 8 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 31 (73.81) | 18.2507 |
| 2000's | 11 (26.19) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (28.44) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 12 (25.00%) | 5.53% |
| Reviews | 13 (27.08%) | 6.00% |
| Case Studies | 1 (2.08%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 22 (45.83%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||